Takeda’s Adcetris (brentuximab vedotin) + AVD Receives EU Approval for

 Shots: The approval is based on P-III ECHELON-1 study result assessing Adcetris + AVD (adriamycin, vinblastine and dacarbazine) vs ABVD (adriamycin, bleomycin, vinblastine and dacarbazine) in patients with previously untreated CD30-positive and has met its 1EPs with 23% reduction in risk progression & improvement in PFS According to 2009 deal b/w Seattle Genetics & Takeda […]Read More


Seattle Genetics’ Adcetris (brentuximab vedotin) Receives FDA’s Breakthrough Designation for

Shots: The FDA’s BT designation is based on P-III ECHELON-2 study results assessing Adcetris + CHP vs CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in 450 patients with CD30+ T-cell lymphoma across North America, EU and Asia The P-III ECHELON-2 study results: met it’s 1EPs & 2EPs; improvement in PFS, superior OS; CRR and ORR were statistically […]Read More